A Two-Part Study Consisting of a Randomized, Placebo-Controlled, Single Dose Safety and Tolerability Study (Part A) Evaluating a Supratherapeutic Dose of Zanubrutinib Followed by a Randomized, Placebo- and Positive-Controlled, Crossover Study (Part B) to Evaluate the Effect of Zanubrutinib on Cardiac Repolarization in Healthy Volunteers
Latest Information Update: 04 Nov 2019
At a glance
- Drugs Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors BeiGene
- 24 May 2018 Status changed from recruiting to completed.
- 16 Feb 2018 New trial record